
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …

Mike Elliott, Vice President of Medical Affairs at Gilead (pictured, right), chats about the company’s sponsorship of a ‘A life …

Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and …

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …

Gilead has announced that Dr Norbert Bischofberger, its Chief Scientific Officer (CSO), Executive Vice President of Research and Development and …

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …